George Chen (D3 Bio)
Here's a $200M China startup idea — if you can read beyond the big words
What does it take to gather $200 million from top VC players in China these days?
Not much that can be shared publicly, D3 Bio suggests as it launches with the hefty Series A this morning. But the ingredients feeding into the Shanghai-based aspiring global biotech may be indicative of things that would turn heads at places like Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
